Commitments and Contingencies - Narrative (Details) - USD ($)			3 Months Ended
	Dec. 20, 2024	Dec. 19, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Loss Contingencies [Line Items]
Accrued clinical and contract manufacturing expense			$ 1,300,000		$ 3,600,000
Incurred collaboration and supply agreement expense			0	$ 200,000
Research and development			8,788,000	$ 13,593,000
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Loss Contingencies [Line Items]
Research and development	$ 6,000,000
Non-refundable payment due		$ 38,000,000	$ 0
Upfront payment period		120 days
Royalty period		10 years
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Development Milestones
Loss Contingencies [Line Items]
Maximum aggregate milestone payments		$ 265,000,000
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Commercial Milestones
Loss Contingencies [Line Items]
Maximum aggregate milestone payments		$ 540,000,000